Acridinecarboxamide topoisomerase poisons:: Structural and kinetic studies of the DNA complexes of 5-substituted 9-amino-(N-(2-dimethylamino)ethyl)acridine-4-carboxamides

被引:38
作者
Adams, A [1 ]
Guss, JM
Collyer, CA
Denny, WA
Prakash, AS
Wakelin, LPG
机构
[1] Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia
[2] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc, Res Ctr, Auckland 1, New Zealand
[3] Natl Ctr Environm Toxicol, Coopers Plains, Qld, Australia
[4] Univ New S Wales, Sch Physiol & Pharmacol, Kensington, NSW 2033, Australia
关键词
D O I
10.1124/mol.58.3.649
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For a series of antitumor-active 5-substituted 9-aminoacridine-4-carboxamide topoisomerase II poisons, we have used X-ray crystallography and stopped-flow spectrophotometry to explore relationships between DNA binding kinetics, biological activity, and the structures of their DNA complexes. The structure of 5-F-9-amino-[N-(2-dimethylamino)ethyl]-acridine-4-carboxamide bound to d(CGTACG)(2) has been solved to a resolution of 1.55 Angstrom in space group P6(4). A drug molecule intercalates between each of the CpG dinucleotide steps, its protonated dimethylamino group partially occupying positions close to the N7 and O6 atoms of guanine G2 in the major groove. A water molecule forms bridging hydrogen bonds between the 4-carboxamide NH and the phosphate group of the same guanine. Intercalation unwinds steps 1 and 2 by 12 degrees and 8 degrees, respectively compared with B-DNA, whereas the central TpA step is overwound by 10 degrees. Nonphenyl 5-substituents, on average, decrease mean DNA dissociation rates by a factor of three, regardless of their steric, hydrophobic, H-bonding, or electronic properties. Cytotoxicity is enhanced on average 4-fold and binding affinities rise by 3-fold, thus there is an apparent association between kinetics, affinity, and cytotoxicity. Taken together, the structural and kinetic studies imply that the main origin of this association is enhanced stacking interactions between the 5-substituent and cytosine in the CpG binding site. Ligand-dependent perturbations in base pair twist angles and their consequent effects on base pair-base pair stacking interactions may also contribute to the stability of the intercalated complex. 5-Phenyl substituents modify dissociation rates without affecting affinities, and variations in their biological activity are not correlated with DNA binding properties, which suggests that they interact directly with the topoisomerase protein.
引用
收藏
页码:649 / 658
页数:10
相关论文
共 33 条
  • [1] Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2
    Adams, A
    Guss, JM
    Collyer, CA
    Denny, WA
    Wakelin, LPG
    [J]. BIOCHEMISTRY, 1999, 38 (29) : 9221 - 9233
  • [2] [Anonymous], SHELX97 MANUAL
  • [3] POTENTIAL ANTITUMOR AGENTS .43. SYNTHESIS AND BIOLOGICAL-ACTIVITY OF DIBASIC 9-AMINOACRIDINE-4-CARBOXAMIDES, A NEW CLASS OF ANTITUMOR AGENT
    ATWELL, GJ
    CAIN, BF
    BAGULEY, BC
    FINLAY, GJ
    DENNY, WA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (11) : 1481 - 1485
  • [4] POTENTIAL ANTITUMOR AGENTS .50. INVIVO SOLID-TUMOR ACTIVITY OF DERIVATIVES OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE
    ATWELL, GJ
    REWCASTLE, GW
    BAGULEY, BC
    DENNY, WA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (04) : 664 - 669
  • [5] BAGULEY BC, 1995, CANCER CHEMOTH PHARM, V36, P244, DOI 10.1007/BF00685854
  • [6] SEQUENCE SPECIFICITY OF THE BINDING OF 9-AMINOACRIDINE-CARBOXAMIDE AND AMSACRINE-4-CARBOXAMIDE TO DNA STUDIED BY DNASE-I FOOTPRINTING
    BAILLY, C
    DENNY, WA
    MELLOR, LE
    WAKELIN, LPG
    WARING, MJ
    [J]. BIOCHEMISTRY, 1992, 31 (13) : 3514 - 3524
  • [7] *BIOS MSI, 1995, INS 2 US GUID
  • [8] INTERACTIONS OF ACRIDINE ANTITUMOR AGENTS WITH DNA - BINDING-ENERGIES AND GROOVE PREFERENCES
    CRENSHAW, JM
    GRAVES, DE
    DENNY, WA
    [J]. BIOCHEMISTRY, 1995, 34 (41) : 13682 - 13687
  • [9] Denny W A, 1997, Expert Opin Investig Drugs, V6, P1845, DOI 10.1517/13543784.6.12.1845
  • [10] DENNY WA, 1986, ANTI-CANCER DRUG DES, V1, P141